title: Advanced glycation end products are elevated in cystic fibrosis-related diabetes and correlate with worse lung function.
abstract: The onset of cystic fibrosis-related diabetes (CFRD) exacerbates lung function decline and increases mortality. One pathway that may worsen the lung dysfunction associated with CFRD is that of the receptor for advanced glycation end products (RAGE) and its ligands.
  
  
  
  Human plasma was obtained from age-matched healthy, CF and CFRD patients. Plasma RAGE ligands (i.e. advanced glycation end products, S100A12, and high-mobility group protein B1) and soluble RAGE (sRAGE) levels were measured.
  
  
  
  CFRD patients had elevated plasma levels of AGEs and S100A12. Soluble RAGE, a RAGE ligand decoy receptor, was not significantly different between groups. Plasma AGE levels and S100A12 levels had significantly negative correlations with FEV1.
  
  
  
  AGEs are significantly elevated in CFRD and correlate negatively with FEV1. CFRD patients did not have significant increases in the decoy sRAGE, suggesting there may be heightened binding and activation of RAGE in CFRD exacerbating activation of proinflammatory pathways.
authors.affiliation: Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Emory University, Atlanta, GA, USA; Emory+Children's Center for Cystic Fibrosis and Airways Disease Research, Emory University, Atlanta, GA, USA; Children's Healthcare of Atlanta, Atlanta, GA, USA. Electronic address: randy.hunt@emory.edu.
authors.forename: William R
authors.initials: WR
authors.lastname: Hunt
authors.affiliation: Department of Pediatrics, Division of Pulmonology, Allergy/Immunology, Cystic Fibrosis and Sleep, Emory University, Atlanta, GA, USA; Emory+Children's Center for Cystic Fibrosis and Airways Disease Research, Emory University, Atlanta, GA, USA; Children's Healthcare of Atlanta, Atlanta, GA, USA.
authors.forename: Beth R
authors.initials: BR
authors.lastname: Helfman
authors.affiliation: Department of Pediatrics, Division of Pulmonology, Allergy/Immunology, Cystic Fibrosis and Sleep, Emory University, Atlanta, GA, USA; Emory+Children's Center for Cystic Fibrosis and Airways Disease Research, Emory University, Atlanta, GA, USA; Children's Healthcare of Atlanta, Atlanta, GA, USA.
authors.forename: Nael A
authors.initials: NA
authors.lastname: McCarty
authors.affiliation: Department of Physiology and Developmental Biology, Brigham Young University, Provo, UT, USA.
authors.forename: Jason M
authors.initials: JM
authors.lastname: Hansen
mesh_terms: D000293:Adolescent; D000328:Adult; D003550:Cystic Fibrosis / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology; D003920:Diabetes Mellitus / Q000097:blood* / Q000175:diagnosis / Q000209:etiology; D005260:Female; D005541:Forced Expiratory Volume; D017127:Glycation End Products, Advanced / Q000097:blood*; D006801:Humans; D008297:Male; D062072:Patient Acuity; D000067759:Receptor for Advanced Glycation End Products / Q000097:blood*; D012042:Registries / Q000706:statistics & numerical data; D012129:Respiratory Function Tests / Q000379:methods*; D000067616:S100A12 Protein / Q000097:blood*; D013223:Statistics as Topic; D014481:United States
chemical_list: D017127:Glycation End Products, Advanced; D000067759:Receptor for Advanced Glycation End Products; D000067616:S100A12 Protein
keywords: Advanced glycation end products; Cystic fibrosis; Cystic fibrosis-related diabetes; Receptor for advanced glycation end products